Neuralstem, Inc.

Oct 30, 2019

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases

Sep 24, 2019

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Aug 07, 2019

Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

Jul 31, 2019

Neuralstem Closes $7.5 Million Underwritten Public Offering

Jul 16, 2019

Neuralstem Announces a 1-for-20 Reverse Stock Split

Jul 01, 2019

Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Jun 26, 2019

Stem Cell Line Shows Potential in Helping Recover Motor Function After a Stroke

May 16, 2019

Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells

May 14, 2019

Neuralstem Reports First Quarter 2019 Fiscal Results

May 06, 2019

Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors

Feb 07, 2019

Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort

Aug 28, 2018

Hiring of Investment Banker Crucial to Neuralstem Success